Bionovo, Inc., a development stage company, engages in the discovery and development of drugs in the areas of cancer and women?s health primarily in the United States. It develops drugs to treat breast and ovarian cancers, and for menopause. The company?s product and drug pipeline includes MF101, a selective estrogen receptor beta agonist, which is designed to alleviate the symptoms of menopause, including hot flashes, night sweats, and bone mineral loss; and BZL101, an apoptosis inducing factor translocator/activator, which is used as an anticancer agent for breast and ovarian cancers, as well as used for the treatment of other solid tumors. In addition, its drug pipeline, which is not entered human clinical trials includes AA102, an apoptosis inducer, which is used as an anticancer agent that attenuates mitochodrial membrane potential to cause a cytochrome c release and caspase activation to induce apoptosis; and VG101, vasodilator and an antimicrobial agent, which is an intra-vaginal gel for the treatment of postmenopausal vaginal dryness. The company has collaboration with the University of California at San Francisco; University of California at Berkeley; University of California at Davis; University of Texas, Southwestern; and University of Colorado Health Sciences College. Bionovo was founded in 2002 and is headquartered in Emeryville, California.